Liraglutide

WikiDoc Resources for Liraglutide
Articles
Most recent articles on Liraglutide Most cited articles on Liraglutide Review articles on Liraglutide Articles on Liraglutide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Liraglutide Images of Liraglutide Photos of Liraglutide Podcasts & MP3s on Liraglutide Videos on Liraglutide
Evidence Based Medicine
Cochrane Collaboration on Liraglutide Bandolier on Liraglutide TRIP on Liraglutide
Clinical Trials
Ongoing Trials on Liraglutide at Clinical Trials.gov Trial results on Liraglutide Clinical Trials on Liraglutide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Liraglutide NICE Guidance on Liraglutide NHS PRODIGY Guidance FDA on Liraglutide CDC on Liraglutide
Books
Books on Liraglutide
News
Liraglutide in the news Be alerted to news on Liraglutide News trends on Liraglutide
Commentary
Blogs on Liraglutide
Definitions
Definitions of Liraglutide
Patient Resources / Community
Patient resources on Liraglutide Discussion groups on Liraglutide Patient Handouts on Liraglutide Directions to Hospitals Treating Liraglutide Risk calculators and risk factors for Liraglutide
Healthcare Provider Resources
Symptoms of Liraglutide Causes & Risk Factors for Liraglutide Diagnostic studies for Liraglutide Treatment of Liraglutide
Continuing Medical Education (CME)
CME Programs on Liraglutide
International
Liraglutide en Espanol Liraglutide en Francais
Business
Liraglutide in the Marketplace Patents on Liraglutide
Experimental / Informatics
List of terms related to Liraglutide

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Liraglutide

File:Liraglutide structure.svg
Clinical data
Synonyms	Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Routes of administration	Subcutanous
ATC code	A10BX07 (WHO)
Pharmacokinetic data
Bioavailability	N/A
Elimination half-life	11-15 hours
Identifiers
IUPAC name L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-glycine
CAS Number	204656-20-2
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C172H265N43O51
Molar mass	3751.20 g/mol

Liraglutide or (NN2211) is a glucagon-like peptide-1 (GLP-1) analog that is being developed by Novo Nordisk under the brand-name "Victoza" for the treatment of type 2 diabetes.

Pharmacodynamics

Studies to date suggest liraglutide improves control of blood glucose.

It reduces meal-related hyperglycaemia (for 12 hours after administration) by increasing insulin secretion, delaying gastric emptying, and suppressing prandial glucagon secretion.

Liraglutide may have advantages over current therapies:

• It acts in a glucose-dependent manner, meaning that it will stimulate insulin secretion only when blood glucose levels are higher than normal. Consequently, it shows negligible risk of hypoglycemia.
• It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
• It decreases appetite and maintains body weight, as shown in a head-to-head study versus glimepiride.
• It lowers blood triglyceride levels.
• It has only mild and transient side effects, mainly gastrointestinal.

Pharmacokinetics

Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetes. GLP-1, in its natural form, is short-lived in the body (the half-life after subcutaneous injection is approximately one hour), so it is not very useful as a therapeutic agent. However, liraglutide has a half-life after subcutaneous injection of 11–15 hours, making it suitable for once-daily dosing (in contrast to Byetta's twice daily).

The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at one position of the GLP-1 molecule, enabling it to bind to albumin within the subcutaneous tissue and bloodstream. The active GLP-1 is then released from albumin at a slow, consistent rate. Binding with albumin also results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-1.

See also

• Glucagon-like peptide-1 analog
• incretin